Extract from our Nordic M&A Newsletter

Read more about our Nordic M&A Newsletter service including the M&A Portal and Private Equity Portfolio Tracker.
Lundbeck to acquire US-based Abide for USD 250m
May 6, 2019

Lundbeck A/S has today signed an agreement to acquire Abide Therapeutics Inc. The purchase price is USD 250m upfront with a potential earn-out of USD 150m. Abide develops among other treatment for Tourette Syndrome. After closing, Abide’s laboratory in California will become a U.S. drug discovery hub for Lundbeck.

ⓘ This story was originally featured in our daily Nordic M&A Newsletter - we publish some of the newsletter content with delay through our M&A Newsletter Library. If you would like more insights on this deal or industry then send us an email at requests@nordicknowledgepartners.com